Table 1.

The pregnancy-related characteristics of patients with NMOSD with AQP4-ab and MOG-ab

	AQP4 cohort	MOG cohort
Number of patients/number of patients with pregnancies after disease onset	83/50	21/5
Number of informative pregnancies/number of pregnancies after disease onset	108/66	21/5
Number of total pregnancy-related attacks	126	28
Age at disease onset, year, mean±SD	25.8±6.3	26.7±5.9
Age at delivery/abortion, year, mean±SD	28.4±4.6	28.3±3.6
AQP4-ab or MOG-ab titre, median (range)	1:32 (1:10–1:3200)	1:32 (1:10–1:320)
Number of pregnancy-related attacks (%)
DP1	13 (10.3)	2 (7.1)
DP2	9 (7.1)	1 (3.6)
DP3	4 (3.2)	0 (0)
PP1	51 (40.5)	11 (39.3)
PP2	25 (19.8)	5 (17.9)
PP3+4	24 (19.0)	9 (32.1)
Number of different pregnancy outcomes or complications (%)
Term delivery	60 (55.6)	18 (85.7)
Premature delivery	5 (4.6)	1 (4.8)
Elective abortion	39 (36.1)	2 (9.5)
Spontaneous abortion	4 (3.7)	0 (0)
Neonatal malformation	3 (2.8)	0 (0)
Pre-eclampsia	0 (0)	0 (0)
BP-ARR mean (95% CI)	0.33 (0.19 to 0.47)	0.40 (0.26 to 0.54)
Adjusted BP-ARR* mean (95% CI)	0.33 (0.26 to 0.41)	–
PP-ARR mean (95% CI)	0.65 (0.46 to 0.84)	0.60 (0.38 to 0.82)
Adjusted PP-ARR* mean (95% CI)	0.69 (0.61 to 0.78)	–

*ARR was adjusted using a Poisson regression for treatment variables (inadequate or adequate treatment) during 12–0 months prepregnancy and during 0–12 months after delivery/abortion.

AQP4-ab, aquaporin-4 antibody; ARR, annualised relapse rate; BP, before pregnancy; DP, during pregnancy; MOG-ab, myelin oligodendrocyte glycoprotein antibody; NMOSD, neuromyelitis optica spectrum disorder; PP, postpartum period.;